1,918 results on '"Berger, Michael F."'
Search Results
2. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment
3. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
4. Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer
5. Precision oncology: current and future platforms for treatment selection
6. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
7. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
8. High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer
9. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival
10. The context-specific role of germline pathogenicity in tumorigenesis
11. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers
12. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
13. Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors
14. Unique Genomic Alterations and Microbial Profiles Identified in Patients With Gastric Cancer of African, European, and Asian Ancestry: A Novel Path for Precision Oncology
15. Germline drivers of gynecologic carcinosarcomas
16. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
17. Genomic mapping of metastatic organotropism in lung adenocarcinoma
18. Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma
19. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
20. Table S15 from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
21. Figure S5: GDD-ENS Performance Across Purity Values from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
22. Figure S3: Confusion Matrix Across All Confidence Predictions from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
23. Figure S4: Ancestry Accuracy Differentials from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
24. Figure S6: Individual Type Shapley Values from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
25. Figure S1: Accuracy of Feature-Specific Classifiers from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
26. Figure S2: GDD-ENS Precision Recall Curves from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
27. Figure S7: Individual Type Shapley Values - Broad Categories from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
28. Supplementary Methods from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
29. Figure S8: Organ Shapley Value Distributions from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
30. Figure S11: Heatmap of Labels Mapped for Adaptable Prior Distributions from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
31. Figure S12: Results flow for Met Site, Histology Prior from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
32. Figure S10: KRAS Shapley Values across typesSupplementary Data from Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
33. Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction
34. MSK-ACCESS powered with SOPHiA DDM: Performance analysis of a decentralized MSK-ACCESS solution.
35. Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.
36. Tracking the FDA precision oncology drug approval landscape in OncoKB.
37. Machine learning predictions improve identification of real-world cancer driver mutations
38. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas
39. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
40. Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
41. Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
42. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
43. ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
44. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
45. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing
46. GENOMIC CHARACTERIZATION OF HIGH-GRADE TA UROTHELIAL CARCINOMA WITH AND WITHOUT CARCINOMA IN SITU
47. Deep Learning Model for Tumor Type Prediction using Targeted Clinical Genomic Sequencing Data
48. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms
49. Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages
50. Figure S1 from Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.